Home > News > Increasing US investment support for Starpharma
April 6th, 2006
Increasing US investment support for Starpharma
Abstract:
Starpharma (ASX:SPL, USOTC:SPHRY) is capitalising on growing US investor interest in the company and its lead product VivaGelTM for the prevention of sexually transmitted infections. Starpharma’s American Depository Receipts (ADR) Program has been strongly supported since its inception in January 2005 and the number of ADRs outstanding has been growing at an average rate of 9% per month, increasing to more than 15% per month in early 2006.
Source:
pharmalive.com
Bookmark:
Investments/IPO's/Splits
QWave Fund Powers Physics and Materials Science-Based Innovation With Initial Round of Venture Capital Investments: New VC Fund Invests Total of $7M in Nano-Meta Technologies, Centice and Clifton June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Announcements
Less is More: Novel Cellulose Structure Requires Fewer Enzymes to Process Biomass to Fuel June 19th, 2013
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
Financial Reports
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013
Arrowhead Reports Fiscal 2013 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time May 9th, 2013
Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013